Recent News

• 02.27.2025 - The Market for Regenerative Medicine to Hit $235.98 Billion by 2032
• 02.12.2025 - Trump’s Massive Investment in AI Cancer Vaccines
• 02.06.2025 - CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders
• 01.29.2025 - Breakthroughs Hope to Make CAR T-cell Cancer Therapies More Affordable
• 01.15.2025 - Malaysia and Singapore, Home to CytoMed Therapeutics, Launch Special Economic Zone to Attract Global Investment
• 12.17.2024 - Breakthroughs in CAR T-Cell Therapies Target Solid Cancer Tumors
• 12.04.2024 - The Massive Global Market For CAR-T Cell Therapies
• 11.20.2024 - Cancer Researchers Show NKT Cells Produced “Significant” Anti-tumor Activity
• 11.06.2024 - New Research Shows Regenerative Medicine Market To Reach $154 Billion by 2033

Recent Filings

• 01.06.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 01.06.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.06.2025 - EX-99.1 EX-99.1
• 12.05.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.20.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.04.2024 - 144 Report of proposed sale of securities
• 10.07.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.03.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.30.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.24.2024 - 6-K/A Report of foreign issuer [Rules 13a-16 and 15d-16]